4.2 Article

Validity of health insurance data to identify people with epilepsy

Journal

EPILEPSY RESEARCH
Volume 139, Issue -, Pages 102-106

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.eplepsyres.2017.11.019

Keywords

Epilepsy; Administrative health data; Accuracy; Prevalence

Funding

  1. Dutch National Epilepsy Fund
  2. ZonMW
  3. NUTS Ohra Fund
  4. Medtronic
  5. AC Thomson Foundation
  6. UCB
  7. GSK
  8. Eisai
  9. Teva
  10. Lundbeck
  11. UK Department of Health's National Institute for Health Research Biomedical Research Centres
  12. Dr Marvin Weil Epilepsy Research Fund

Ask authors/readers for more resources

Background. Large administrative databases may prove useful to assess epilepsy-related comorbidity and mortality. Despite their increased use, their validity as data source in epilepsy is yet under-ascertained. Methods: Achmea is a large Dutch health insurance company covering about 25% of the population. We performed a retrospective cohort study using data from the Achmea Health Insurance Database (AHID) over the period 2006-2009. To assess the validity of epilepsy codes in the AHID, we randomly invited 1000 individuals (age 18-75 years insured by Achmea), attending an epilepsy centre or a district hospital during 2006-2009, to participate. Informed consent was provided and 293 were eligible for inclusion. We compared the diagnostic codes for epilepsy in AHID with the diagnosis in their case-notes (reference standard). As additional measure of validity, we compared prevalence of epilepsy codes in AHID (based on anonymized data of all 26.297 subjects with this code in AHID) with epilepsy prevalence rates in the general Dutch population to estimate an age specific standardized prevalence ratio. Results: We identified 293 participants with an epilepsy code in AHID. The majority (278) of them had a definite or possible diagnosis of epilepsy in the case-notes; i.e. a positive predictive value of 0.95 (95% CI 0.92-0.97). The overall prevalence of epilepsy codes in the AHID was slightly higher than the putative prevalence in the general Dutch population (7.4/1.000 vs. 6.8/1.000) with a Standardized Prevalence Ratio of 1.08 (95% CI: 1.08-1.09). Conclusions: Our findings demonstrate the validity of AHID data for a diagnosis of epilepsy and confirm previous work on using administrative data for epilepsy research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available